Omeros Return on Tangible Equity 2012-2025 | OMER
Current and historical return on tangible equity values for Omeros (OMER) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Omeros Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-09-30 | $-0.12B | $-0.22B | 56.74% |
| 2025-06-30 | $-0.12B | $-0.23B | 62.05% |
| 2025-03-31 | $-0.15B | $-0.21B | 89.94% |
| 2024-12-31 | $-0.16B | $-0.18B | 117.07% |
| 2024-09-30 | $-0.13B | $-0.15B | 142.93% |
| 2024-06-30 | $-0.14B | $-0.13B | 238.30% |
| 2024-03-31 | $-0.12B | $-0.07B | 543.82% |
| 2023-12-31 | $-0.12B | $-0.03B | -1275.68% |
| 2023-09-30 | $0.02B | $-0.01B | 54.05% |
| 2023-06-30 | $0.04B | $0.02B | 141.38% |
| 2023-03-31 | $0.05B | $0.06B | 303.23% |
| 2022-12-31 | $0.05B | $0.09B | 9600.00% |
| 2022-09-30 | $0.20B | $-0.05B | -1333.33% |
| 2022-06-30 | $0.19B | $-0.03B | -280.14% |
| 2022-03-31 | $0.20B | $-0.01B | -160.00% |
| 2021-12-31 | $0.19B | $0.02B | -109.76% |
| 2021-09-30 | $-0.12B | $-0.26B | 58.22% |
| 2021-06-30 | $-0.14B | $-0.25B | 82.25% |
| 2021-03-31 | $-0.14B | $-0.22B | 96.79% |
| 2020-12-31 | $-0.14B | $-0.12B | 109.38% |
| 2020-09-30 | $-0.13B | $-0.09B | 105.52% |
| 2020-06-30 | $-0.11B | $-0.16B | 78.97% |
| 2020-03-31 | $-0.09B | $-0.13B | 68.88% |
| 2019-12-31 | $-0.08B | $-0.11B | 66.40% |
| 2019-09-30 | $-0.08B | $-0.14B | 63.54% |
| 2019-06-30 | $-0.10B | $-0.13B | 91.82% |
| 2019-03-31 | $-0.12B | $-0.12B | 132.24% |
| 2018-12-31 | $-0.13B | $-0.10B | 185.40% |
| 2018-09-30 | $-0.12B | $-0.09B | 271.19% |
| 2018-06-30 | $-0.09B | $-0.06B | 445.57% |
| 2018-03-31 | $-0.07B | $-0.03B | 348.72% |
| 2017-12-31 | $-0.05B | $0.00B | 218.56% |
| 2017-09-30 | $-0.06B | $0.01B | 170.99% |
| 2017-06-30 | $-0.06B | $-0.06B | 154.60% |
| 2017-03-31 | $-0.06B | $-0.05B | 157.96% |
| 2016-12-31 | $-0.07B | $-0.04B | 181.33% |
| 2016-09-30 | $-0.07B | $-0.02B | 195.68% |
| 2016-06-30 | $-0.07B | $-0.05B | 236.80% |
| 2016-03-31 | $-0.08B | $-0.04B | 458.82% |
| 2015-12-31 | $-0.08B | $-0.03B | 6080.00% |
| 2015-09-30 | $-0.08B | $-0.01B | 1400.00% |
| 2015-06-30 | $-0.08B | $0.01B | 750.00% |
| 2015-03-31 | $-0.08B | $0.02B | 515.25% |
| 2014-12-31 | $-0.07B | $-0.04B | 389.47% |
| 2014-09-30 | $-0.06B | $-0.03B | 431.37% |
| 2014-06-30 | $-0.05B | $-0.01B | 425.00% |
| 2014-03-31 | $-0.05B | $0.01B | 383.67% |
| 2013-12-31 | $-0.04B | $-0.02B | 228.57% |
| 2013-09-30 | $-0.05B | $-0.02B | 311.86% |
| 2013-06-30 | $-0.05B | $-0.01B | 500.00% |
| 2013-03-31 | $-0.04B | $-0.02B | 355.56% |
| 2012-12-31 | $-0.04B | $-0.01B | 371.43% |
| 2012-09-30 | $-0.04B | $0.00B | 400.00% |
| 2012-06-30 | $-0.04B | $-0.02B | 388.89% |
| 2012-03-31 | $-0.03B | $-0.01B | 2480.00% |
| 2011-12-31 | $-0.03B | $-0.01B | -504.35% |
| 2011-09-30 | $-0.03B | $0.00B | -212.24% |
| 2011-06-30 | $-0.03B | $0.01B | -158.82% |
| 2011-03-31 | $-0.03B | $0.02B | -136.36% |
| 2010-12-31 | $-0.03B | $0.02B | -109.09% |
| 2010-09-30 | $-0.03B | $0.02B | -87.22% |
| 2010-06-30 | $-0.03B | $0.03B | -104.17% |
| 2010-03-31 | $-0.02B | $0.04B | -139.39% |
| 2009-12-31 | $-0.02B | $0.04B | -289.66% |
| 2009-06-30 | $-0.02B | 0.00% | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.861B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $188.859B | 21.09 |
| EssilorLuxottica (ESLOY) | France | $145.490B | 0.00 |
| Stryker (SYK) | United States | $137.164B | 27.23 |
| Boston Scientific (BSX) | United States | $135.332B | 30.95 |
| Medtronic (MDT) | Ireland | $129.919B | 18.00 |
| Medline (MDLN) | United States | $60.378B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.195B | 0.00 |
| Agilent Technologies (A) | United States | $39.301B | 24.84 |
| GE HealthCare Technologies (GEHC) | United States | $37.303B | 17.84 |
| ResMed (RMD) | United States | $37.266B | 25.79 |
| Koninklijke Philips (PHG) | Netherlands | $28.637B | 18.70 |
| Terumo (TRUMY) | Japan | $20.358B | 22.92 |
| Insulet (PODD) | United States | $19.697B | 61.13 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.349B | 10.82 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.055B | 0.00 |
| Baxter (BAX) | United States | $10.317B | 8.33 |
| Sunny Optical Technology (SNPTF) | China | $9.589B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.233B | 29.60 |
| Demant (WILYY) | Denmark | $7.372B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $4.455B | 13.57 |
| BillionToOne (BLLN) | United States | $4.145B | 0.00 |
| Envista Holdings (NVST) | United States | $4.014B | 23.03 |
| ICU Medical (ICUI) | United States | $3.914B | 24.85 |
| Haemonetics (HAE) | United States | $3.278B | 14.59 |
| Prestige Consumer Healthcare (PBH) | United States | $3.257B | 14.85 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.099B | 0.00 |
| Neogen (NEOG) | United States | $2.159B | 47.26 |
| QuidelOrtho (QDEL) | United States | $2.076B | 13.35 |
| Perrigo (PRGO) | Ireland | $2.075B | 5.20 |
| AtriCure (ATRC) | United States | $1.990B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.945B | 39.15 |
| Curaleaf Holdings (CURLF) | Canada | $1.764B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.687B | 16.85 |
| Green Thumb Industries (GTBIF) | United States | $1.649B | 72.27 |
| Kestra Medical Technologies (KMTS) | United States | $1.442B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.422B | 20.59 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.390B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.251B | 371.14 |
| Capricor Therapeutics (CAPR) | United States | $1.105B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.064B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.979B | 0.00 |
| InMode (INMD) | Israel | $0.890B | 10.06 |
| Valneva SE (VALN) | France | $0.886B | 0.00 |
| CeriBell (CBLL) | United States | $0.842B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.602B | 16.32 |
| Verano Holdings (VRNO) | United States | $0.516B | 0.00 |
| Cerus (CERS) | United States | $0.503B | 0.00 |
| Brainsway (BWAY) | Israel | $0.474B | 80.63 |
| Canopy Growth (CGC) | Canada | $0.431B | 0.00 |
| SNDL (SNDL) | Canada | $0.428B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.426B | 0.00 |
| Quanterix (QTRX) | United States | $0.337B | 0.00 |
| Evolus (EOLS) | United States | $0.329B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.309B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.282B | 22.51 |
| TriSalus Life Sciences (TLSI) | United States | $0.274B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.245B | 144.33 |
| TerrAscend (TSNDF) | Canada | $0.243B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.235B | 0.00 |
| High Tide (HITI) | Canada | $0.230B | 0.00 |
| Organigram Global (OGI) | Canada | $0.219B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Utah Medical Products (UTMD) | United States | $0.199B | 17.54 |
| Sanara MedTech (SMTI) | United States | $0.198B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.195B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.183B | 0.00 |
| Accendra Health (ACH) | United States | $0.163B | 1.64 |
| Quipt Home Medical (QIPT) | United States | $0.158B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.155B | 0.00 |
| Apyx Medical (APYX) | United States | $0.151B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.132B | 0.00 |
| Fonar (FONR) | United States | $0.116B | 16.77 |
| Jushi Holdings (JUSHF) | United States | $0.114B | 0.00 |
| MacroGenics (MGNX) | United States | $0.111B | 0.00 |
| Exagen (XGN) | United States | $0.111B | 0.00 |
| Biote (BTMD) | United States | $0.104B | 4.56 |
| Sharps Technology (STSS) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 25.23 |
| Nephros (NEPH) | United States | $0.050B | 35.85 |
| Rockwell Medical (RMTI) | United States | $0.044B | 0.00 |
| Veru (VERU) | United States | $0.043B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.042B | 0.00 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| Bonk (BNKK) | United States | $0.034B | 0.00 |
| United-Guardian (UG) | United States | $0.030B | 15.27 |
| Jin Medical (ZJYL) | China | $0.020B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.017B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.016B | 0.00 |
| INLIF (INLF) | China | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Flora Growth (FLGC) | United States | $0.007B | 0.00 |
| Agape ATP (ATPC) | $0.004B | 0.00 | |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |